1 March 2023 in Turkish Archives of Pediatrics
Objective: Juvenile idiopathic arthritis is a heterogeneous group of disorders and is the most common rheumatic condition in childhood. There are scarce data regarding all comorbidities in juvenile idiopathic arthritis patients. Materials and Methods: We aimed to identify the non-rheumatic comorbidities in our juvenile idiopathic arthritis patients. Data were obtained cross-sectionally from the medical records and the face-to-face interviews for 6 consecutive months. Those with more than 1 rheumatic disease were excluded, and conditions that were highly related to the disease, such as uveitis, were not taken into account. Results: The study included 459 patients with female dominance (62.1%, n = 285). The median age of the patients was 12.87 (1.53-20.95) years. One hundred fifty patients (32.7%) had at least 1 comorbidity (5 patients had 3 comorbidities, and 24 patients had 2 comorbidities). The most common 3 non-rheumatic accompanying medical conditions in our patients were allergic rhinitis (n = 37, 8.1%), attention-deficit hyperactivity disorder (n = 35, 7.6%), and atopic dermatitis (n = 28, 6.1%). None of our patients with systemic JIA had any autoimmune disease. All the patients with primary immune deficiencies had anti-nuclear antibody positivity. Conclusion: Almost one-third of our patients had at least one comorbidity. This finding might be very helpful to us in planning our multi-disciplinary approach to our patients. Cite this article as: Haşlak F, Guliyeva V, Hotaman B, et al. Non-rheumatic chronic comorbidities in children with juvenile idiopathic arthritis. Turk Arch Pediatr. 2023;58(2):212-219.
1 August 2024 in The Journal of Rheumatology
Objective: This study aimed to provide a comprehensive overview of the clinical features, laboratory and screening results, treatment options, and outcomes of patients with type I interferonopathy. Our secondary goal was to identify the predictors of long-term morbidity or mortality.Methods: We included children with genetically confirmed type I interferonopathies, with a follow-up duration of > 1 year. Data were obtained retrospectively from medical records.Results: Of the 40 eligible patients for the study, 52.5% were female, with a median age of disease onset of 1.5 years (range 0.1-13.2 yrs). They were diagnosed at an average age of 6.8 (SD 4.6) years. Aicardi-Goutières syndrome was the most common diagnosis (n = 15, 37.5%). The central nervous system was the most frequently affected system (n = 27, 67.5%). Janus kinase inhibitors were administered to 17 (42.5%) patients. Twenty-five patients (62.5%) developed at least 1 permanent morbidity or died during follow-up; thus, they were included in the poor outcome group. Although younger age at disease onset, intracranial calcification (ICC), and lack of chilblains and elevated acute-phase reactants were significant in univariate logistic regression analysis, only ICC on magnetic resonance imaging at admission (adjusted odds ratio 19.69, 95% CI 1.08-359.05,P= 0.04) was found to be a significant predictor of poor outcomes in multivariate logistic regression analysis.Conclusion: For the first time, we evaluated the predictors of poor outcomes in patients with type I interferonopathy with a broad spectrum of subtypes. Further, our study’s unique patient characteristics can provide valuable insights into these extremely rare conditions.
4 August 2026 in The Pediatric Infectious Disease Journal
Was not provided for this article.
16 July 2026 in BMC Endocrine Disorders
Children with idiopathic short stature (ISS) have reduced height potential without identifiable endocrine or systemic causes. Selecting appropriate candidates for recombinant human growth hormone (rhGH) therapy remains challenging. The aim of this study was to describe near-final height (NFH) outcomes and to identify clinical predictors of growth response in children with ISS who were selected for rhGH therapy based on a positive IGF-1 generation test (IGFGT). In this multicenter retrospective study (2009-2018) across four centers in Türkiye, patients diagnosed with ISS, baseline IGF-1 < 0 SDS, and ≥ 20% IGF-1 increment after IGFGT were included. GH1 gene sequencing was performed to exclude biologically inactive GH, a condition marked by normal or elevated GH secretion but impaired biological activity. NFH was defined as bone age ≥ 14 years in girls and ≥ 16 years in boys. Height SDS gain from baseline to NFH was evaluated. Sixty-three patients (28 females, 19 pubertal) were enrolled, of whom 55 had NFH data and were included in the final analysis. Mean age at treatment initiation was 10.8 ± 3.0 years. No GH1 mutations were identified. Among 55 patients with NFH data, mean height SDS increased from - 2.90 ± 0.77 at baseline to -1.92 ± 0.90 at NFH (p < 0.001), with a mean height SDS gain of 0.93 ± 0.68. The median difference between NFH SDS and baseline predicted adult height (PAH) SDS was - 0.06 (- 0.32-0.07). Predictors of NFH gain included female gender, target height (TH) SDS, baseline height-TH difference, baseline height-PAH difference, and first-year growth velocity SDS. rhGH therapy was associated with improvements in height SDS and NFH in this selected cohort of children with ISS. However, the absence of an untreated control group and the minimal difference between NFH and baseline PAH indicate that these findings should be interpreted with caution. Although no GH1 mutations were identified, the relatively high rate of parental consanguinity suggests that other genetic factors within the GH-IGF-1 axis or epiphyseal growth plate pathways may underlie the etiology of short stature. Not applicable.